您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > DB2313
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
DB2313
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
DB2313图片
CAS NO:2170606-74-1
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
DB2313 是一种有效的转录因子PU.1抑制剂,apoptosis为 14 nM。DB2313 破坏了PU.1与靶基因启动子的相互作用。DB2313 可诱导急性髓细胞性白血病 (AML) 细胞凋亡 (apoptosis),并具有抗癌作用。
生物活性

DB2313 is a potent transcription factorPU.1inhibitor with anapoptosisof 14 nM. DB2313 disrupts the interaction ofPU.1with target gene promoters. DB2313 inducesapoptosisof acute myeloid leukemia (AML) cells, and has anticancer effects[1].

IC50& Target

IC50: 14 nM (PU.1)[1]

体外研究
(In Vitro)

DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/–acute myeloid leukemia (AML) cells (IC50of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/–AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating[1].
In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters[1].

体内研究
(In Vivo)

DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice[1].

Animal Model:NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/–AML cells[1]
Dosage:17 mg/kg
Administration:Intraperitoneal injection; three times per week; for 3 weeks
Result:Decreased tumor burden and resulted in increased survival.
分子量

708.83

性状

Solid

Formula

C42H41FN8O2

CAS 号

2170606-74-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 3.7 mg/mL(5.22 mM;ultrasonic and warming and heat to 70℃)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.4108 mL7.0539 mL14.1078 mL
5 mM0.2822 mL1.4108 mL2.8216 mL
10 mM---------
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 50%PEG300   50% saline

    Solubility: 5 mg/mL (7.05 mM); Suspended solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。